Your browser doesn't support javascript.
The Uro-oncology Patient and Vaccination Against SARS-CoV-2.
Rodriguez Socarrás, Moises; Gómez Rivas, Juan; Teoh, Jeremy Yuen-Chun; Puente, Javier; Moschini, Marco; Moreno-Sierra, Jesús.
  • Rodriguez Socarrás M; Instituto de Cirugía Urológica Avanzada, Madrid, Spain.
  • Gómez Rivas J; Department of Urology, Hospital Clínico San Carlos, Madrid, Spain.
  • Teoh JY; Department of Surgery, S.H. Ho Urology Centre, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
  • Puente J; Department of Oncology, Hospital Clínico San Carlos, Madrid, Spain.
  • Moschini M; Department of Urology, San Raffaele University and IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy.
  • Moreno-Sierra J; Department of Urology, Hospital Clínico San Carlos, Madrid, Spain.
Eur Urol Open Sci ; 29: 77-81, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1244736
ABSTRACT
As of April 13, 2021, 137 million cases of COVID-19 and 2.95 million deaths have been reported worldwide. On December 21, 2020, the Pfizer-BioNTech vaccine was approved for use in the European Union, with efficacy of 95% protection against COVID-19 infection. Several other vaccines are at different stages of assessment by the European Medicines Agency. In addition to the elderly, oncology patients are a vulnerable population in which COVID-19 infection may be more severe. However, owing to the design of the initial studies, evidence on the safety and efficacy of vaccination against SARS-CoV-2 in these patients is scarce and recommendations are based on the opinion of associations, stakeholders, and experts via extrapolation of information and experience for other vaccines, especially influenza vaccines. Despite the limited evidence, the consensus is that SARS-CoV-2 vaccines are safe and vaccination of oncology patients and their close relatives is recommended, although efficacy may be lower in patients with an impaired immune response and the need for additional booster doses is not yet clear. Recommendations include avoiding the use of vaccines based on viral vectors for patients with an impaired immune response, deferring vaccination for immunosuppressed patients or administering the vaccine before immunosuppression, and avoiding chemotherapy receipt between the two doses of a vaccine or on the same day that the vaccine is administered. These recommendations can be extrapolated to urology patients and although evidence is lacking, there should not be greater interference with SARS-CoV-2 vaccines from androgen deprivation therapy or intravesical bacillus Calmette-Guérin. However, large studies to provide strong evidence for uro-oncology patients are needed. PATIENT

SUMMARY:

We looked at the effects of COVID-19 vaccination for patients with urological cancers. The consensus is that the vaccines are safe, and vaccination of cancer patients and their close relatives is recommended.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: Eur Urol Open Sci Year: 2021 Document Type: Article Affiliation country: J.euros.2021.05.007

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: Eur Urol Open Sci Year: 2021 Document Type: Article Affiliation country: J.euros.2021.05.007